
ETF
L&G Pharma Breakthrough ETF
- ISIN
- IE00BF0H7608
- Category
- Sector Equity Biotechnology
- Minimum investment
- 1 USD
How good is this fund, really?
See the rating in the appAbout L&G Pharma Breakthrough ETF
Biotechnology firms that research, develop or manufacture orphan drugs worldwide are the holdings this Legal & General ETF is built around, via the Solactive Pharma Breakthrough Value Index Net Total Return. LGIM Managers (Europe) Limited runs it passively, buying index shares in index weights, and may use derivatives for efficient management. The fund carries a sustainable investment objective, meaning it favours companies that contribute to social goals, avoid significant harm and follow good governance. The US dollar class accumulates income. Its key information document sets a recommended holding period of 5 years and an ongoing charge of 0.49%.
Watch this fund for free Add L&G Pharma Breakthrough ETF to your watchlist in the PowerFunds app and we tell you when it falls behind the rest of its category.
Watch the fund for freeWhere to buy L&G Pharma Breakthrough ETF — platforms and fees
Sold on 4 platforms we follow.
-
AJ Bell Annual fee: See the platformGo to AJ Bell ↗
-
Fidelity Annual fee: See the platformGo to Fidelity ↗
-
Hargreaves Lansdown Annual fee: See the platformGo to Hargreaves Lansdown ↗
-
interactive investor Annual fee: See the platformGo to interactive investor ↗
L&G Pharma Breakthrough ETF — its category
Sector Equity Biotechnology — PowerFunds rates 55 funds in this category every month.
Biotechnology funds →Other funds
- Global X Genomics & Biotech ETF USD Acc
- International Biotechnology Ord
- Invesco NASDAQ Biotech ETF
- iShares Nasdaq US Biotech ETF USD Acc
- iShares Nasdaq US Biotech ETF USD Dist
- Janus Henderson Hrzn Biotec H2 USD
- JPM Thmtcs Gentc Thrps C dist GBP
- LS ARK Genomic Revolution Trkr ETP Scs
- Pictet-Biotech I dy GBP
- Polar Capital Biotech I Inc
- RTW Biotech Opportunities Ord
- WisdomTree BioRevolution ETF - USD Acc